GlassScriptPhysician profile
Chaitali Dey
NPI 1841238334
$4,501.82
in general payments reported to CMS, 2019-2025
16 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2021: $374 · 2022: $679 · 2023: $2,343 · 2024: $793 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,690 · Consulting Fee: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,690.36 |
| Consulting Fee | $1,575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $2,244.41 | 2019-2024 | Korsuva, Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $735.19 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $296.79 | 2021-2024 | Farxiga, Lokelma |
| Ardelyx, INC. | $296.67 | 2024 | Xphozah 30 Mg, Ibsrela |
| Mallinckrodt Hospital Products INC. | $213.99 | 2023 | Terlivaz |
| Calliditas Therapeutics US INC. | $140.77 | 2024-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $107.63 | 2023 | Velphoro |
| Genzyme Corporation | $99.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $93.06 | 2019-2024 | Jynarque |
| Mozarc Medical US LLC | $75.00 | 2024 | Argyle |
| Opko Pharmaceuticals, LLC | $59.14 | 2022-2025 | Rayaldee |
| Amgen INC. | $38.37 | 2021-2022 | |
| Novo Nordisk INC | $35.71 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $31.17 | 2024-2025 | |
| Scpharmaceuticals INC. | $17.67 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.12 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaitali Dey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.